When did 10X Genomics Inc file this DEFA14A?

10X Genomics Inc (TXG) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 24, 2026. The accession number assigned by EDGAR is 0001628280-26-027204.

What does a DEFA14A disclose?

DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.

What is the key takeaway from this filing?

10x Genomics: No material developments for governance or investors. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.

Where can I find 10X Genomics Inc's prior proxy statements on EDGAR?

The SEC EDGAR browser lists every DEFA14A 10X Genomics Inc has filed under CIK 1770787, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Boardroom Alpha

TXG · Additional Proxy Materials (DEFA14A) · Filed April 24, 2026

10X Genomics Inc — Additional Proxy Materials (DEFA14A)

Form

DEFA14A

Filed

April 24, 2026

Ticker

TXG

Accession

0001628280-26-027204

10X Genomics Inc on Boardroom Alpha View on SEC EDGAR

Boardroom Alpha · Filing insights

10x Genomics: No material developments for governance or investors.

About 10X Genomics Inc

Market cap

$3.9B

1Y TSR

+127.0%

3Y TSR

−24.8%

Board grade

C-

Sector

Healthcare

CEO

Serge Saxonov

Last annual meeting: Jun 4, 2026 · View full 10X Genomics Inc profile →

Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

______________________


Filed by the Registrant			x			Filed by a Party other than the Registrant			o


Check the appropriate box:

o			Preliminary Proxy Statement

o			Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o			Definitive Proxy Statement

x			Definitive Additional Materials

o			Soliciting Material Pursuant to §240.14a-12

10x Genomics, Inc.

(Name of Registrant as Specified In Its Charter)


Payment of Filing Fee (Check the appropriate box):

x			No fee required.


o			Fee paid previously with preliminary materials.

o			Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i) and 0-11

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting Forecast Schedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from 10X Genomics Inc (TXG)

10-QQuarterly Report
May 8, 2026
8-KCurrent Report
May 7, 2026
DEF 14AProxy Statement
Apr 24, 2026
10-KAnnual Report
Feb 13, 2026
8-KCurrent Report
Feb 12, 2026
8-KCurrent Report
Jan 12, 2026
8-KCurrent Report
Nov 14, 2025
10-QQuarterly Report
Nov 7, 2025
8-KCurrent Report
Nov 6, 2025
10-QQuarterly Report
Aug 8, 2025
8-KCurrent Report
Aug 7, 2025
8-KCurrent Report
Jun 5, 2025

Continue researching

Reference

Frequently asked questions

When did 10X Genomics Inc file this DEFA14A?: 10X Genomics Inc (TXG) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 24, 2026. The accession number assigned by EDGAR is 0001628280-26-027204.
What does a DEFA14A disclose?: DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?: 10x Genomics: No material developments for governance or investors. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find 10X Genomics Inc's prior proxy statements on EDGAR?: The SEC EDGAR browser lists every DEFA14A 10X Genomics Inc has filed under CIK 1770787, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer